Evaluation of a Competitive Antibody Enzyme Immunoassay for Specific Diagnosis of Chagas' Disease

Cuña, Washington R.; Rodriguez, Celeste; Torrico, Faustino; Afchain, D.; Loyens, Marc; Desjeux, Philippe

doi:10.2307/3282588

Cited by 6 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, reactivity is retained for approximately one year after production. Another advantage of ESEA antigens compared to other antigenic preparations from epimastigotes is the easy production since they donot need to be sonicated or follow other biochemical procedures to obtain usable antigenic preparations [20, 30, 31]. …”

Section: Discussionmentioning

confidence: 99%

Development and Application of an ELISA Assay Using Excretion/Secretion Proteins from Epimastigote Forms ofT. cruzi(ESEA Antigens) for the Diagnosis of Chagas Disease

Berrizbeitia

Figueroa

Ward

et al. 2012

Journal of Tropical Medicine

View full text Add to dashboard Cite

An indirect enzyme-linked immunoabsorbent assay (ELISA) for Trypanosoma cruzi was developed using epimastigote secretion/excretion proteins (ESEA antigens) obtained from axenic culture supernatants. A panel of 120 serum samples from subjects with confirmed Chagas disease (n = 50), healthy controls (n = 50), and patients with other parasitic diseases (n = 20) was used to evaluate the new ESEA-based ELISA (ELISAESEA). This new test had excellent sensitivity (98%) and acceptable specificity (88%). Cross-reactivity was observed largely in sera from subjects with Leishmania and Ascaris infections. Using Western blotting and epimastigotes from two distinct T. cruzi isolates, several polypeptide bands with molecular masses ranging from 50 to 220 kDa were detected in pooled chagasic sera. However, the band pattern for each isolate was different. These data suggest that an inexpensive and technically simple ELISA based on ESEA antigens is a promising new tool for the diagnosis of Chagas disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and Application of an ELISA Assay Using Excretion/Secretion Proteins from Epimastigote Forms ofT. cruzi(ESEA Antigens) for the Diagnosis of Chagas Disease

Berrizbeitia

Figueroa

Ward

et al. 2012

Journal of Tropical Medicine

View full text Add to dashboard Cite

show abstract

“…Como primer paso para la concepción de un programa de este tipo, el CNDR de Managua, como instituto central de las actividades del Ministerio de Salud, decidió incorporar a su arsenal diag-nóstico una técnica altamente sensible con la cual pudiera realizar el diagnóstico individual y acometer estudios poblacionales a gran escala que permitieran estimar la diseminación de la enfermedad de Chagas en el país y, más tarde, evaluar los programas de control. La técnica seleccionada para estos fines fue una prueba de ELISA en fase sólida, que es una de las técnicas serológicas más sensibles utilizadas para el diagnóstico de la enfermedad de Chagas en su fase crónica (9,10).…”

Section: Discussionunclassified

Detección de anticuerpos contra Trypanosoma cruzi en Somoto, Nicaragua, mediante ELISA indirecto e IFI en muestras de sangre en papel de filtro

Palacios¹,

Belli²,

Espino³

2000

Rev Panam Salud Publica

View full text Add to dashboard Cite

We standardized a solid-phase enzyme-linked immunosorbent assay (ELISA) in order to study the presence of Trypanosoma cruzi antibodies in asymptomatic persons who live in an area of Nicaragua endemic for Chagas' disease. The test was standardized to analyze filter-paper blood samples, which are easy to transport. In the first phase of our investigation, ELISA was used to study 18 samples of total serum and 18 eluates of blood from patients with chronic Chagas' disease; 30 samples of serum and 30 eluates of blood from healthy people, used as negative controls; and 14 samples of serum and 14 eluates of blood from patients with cutaneous or visceral leishmaniasis, which were used to study cross-reactions. Both with the total-serum and the blood-eluate samples, the ELISA test provided 100% sensitivity and 90% specificity. Cross-reactions in the patient samples were observed only with visceral leishmaniasis. The second phase of our investigation was a population study that included eight rural communities in the area of Somoto, Nicaragua. Through random sampling, filter-paper blood samples were collected from 2,434 people (1,335 men and 1,099 women) from the communities of Aguas Calientes, El Brocal, La Manzana, Las Playas, Los Canales, Santa Isabel, Santa Rosa, and Santa Teresa. Studied by ELISA and by indirect immunofluorescence (IIF), the samples included 260 found seropositive by ELISA (10.7%), of which 207 were positive according to IIF (8.5%). With both techniques, the majority of seropositives were among women, but the difference between men and women was not statistically significant. There was a high level of agreement between the results obtained with the two techniques. There was an upward trend with age, with 5.4% of those found seropositive by ELISA being persons 10 years of age or younger and 42.7% of those found seropositive being older than 50. The vast majority of the individuals analyzed were asymptomatic.

show abstract

“…In fact, an extraordinarily wide range of EIAs based on different T. cruzi antigens has been described. These include crude sonicated epimastigotes (Breniere et al , 1985; Almeida et al , 1997; Monteon et al , 1997; Pinho et al , 1999), proteins extracted from epimastigotes (Schechter, 1987; Cuna et al , 1989; Solana et al , 1995; Partel & Rossi, 1998), fixed‐whole epimastigotes (De Hubsch et al , 1988, 1989; Carbonetto et al , 1989; Antas et al , 2000), fixed and sonicated amastigotes (Araujo & Guptill, 1984), sonicated and purified trypomastigote glycoconjugate antigens (Almeida et al , 1997; Aznar et al , 1997), recombinant proteins (Cetron et al , 1992; Godsel et al , 1995; Almeida et al , 1997; da Silveira et al , 2001; Ferreira et al , 2001; Matsumoto et al , 2002) and trypomastigote excretory–secretory antigens (TESA) (Umezawa et al , 1996, 2001; Kesper et al , 2000; Nakazawa et al , 2001; Matsumoto et al , 2002). Epimastigote antigens have been used in most of these studies (84%) due to ease of culture and good antigen yield (Monteon et al , 1997).…”

mentioning

confidence: 99%

Field evaluation of four novel enzyme immunoassays for Chagas’ disease in Venezuela blood banks: comparison of assays using fixed‐epimastigotes, fixed‐trypomastigotes or trypomastigote excreted–secreted antigens from two Trypanosoma cruzi strains

Berrizbeitia

Ndao

Bubis

et al. 2006

Transfusion Medicine

View full text Add to dashboard Cite

SUMMARY. Many serological tests have been developed for the diagnosis of ChagasÕ disease, but few have been subjected to a rigorous field evaluation. We have recently described several novel enzyme immunoassays (EIAs) based on fixed-whole organisms or trypomastigote excretory-secretory antigens (TESA) from different Trypanosoma cruzi strains (Tulahuen or Brazil). This study evaluated the most promising of these novel assays (e.g. fixed-epimastigotes, fixedtrypomastigotes, TESA Brazil and TESA Tulahuen antigens) in a field study of Venezuelan blood bank specimens. The assays were tested in an operatorblinded fashion using 2038 blood bank samples obtained from low and high T. cruzi prevalence regions of Venezuela (n ¼ 1050 and n ¼ 988 from Bolivar and Portuguesa states, respectively). Based on National Laboratory for Chagas Immunodiagnosis (NLCI)Ôgold standardÕ results, all novel EIAs were superior to the commercial kit currently used in Venezuela, achieving 100% sensitivity and >99% specificity at optimal cut-off values. The novel assays identified seven false-negative samples compared with the routine screening performed by the Venezuelan blood bank although two samples were also misclassified as positive. Minor differences in the performance of the four novel assays were observed at lower arbitrary cutoff values. This study confirms the potential utility of both the fixed-organism and the TESA-based assays in the diagnosis of T. cruzi infection.

show abstract

Evaluation of a Competitive Antibody Enzyme Immunoassay for Specific Diagnosis of Chagas' Disease

Cited by 6 publications

References 4 publications

Development and Application of an ELISA Assay Using Excretion/Secretion Proteins from Epimastigote Forms ofT. cruzi(ESEA Antigens) for the Diagnosis of Chagas Disease

Development and Application of an ELISA Assay Using Excretion/Secretion Proteins from Epimastigote Forms ofT. cruzi(ESEA Antigens) for the Diagnosis of Chagas Disease

Detección de anticuerpos contra Trypanosoma cruzi en Somoto, Nicaragua, mediante ELISA indirecto e IFI en muestras de sangre en papel de filtro

Field evaluation of four novel enzyme immunoassays for Chagas’ disease in Venezuela blood banks: comparison of assays using fixed‐epimastigotes, fixed‐trypomastigotes or trypomastigote excreted–secreted antigens from two Trypanosoma cruzi strains

Contact Info

Product

Resources

About